Cagrilintide
Investigational — Human trials in progressWhat it is
A long-acting amylin analogue investigated for appetite regulation, often studied alongside GLP-1 agonists. Investigational.
Cagrilintide is a long-acting amylin analogue studied for appetite regulation, frequently investigated alongside a GLP-1 agonist.
Research context
Studied in relation to:
- Appetite regulation (trial-stage)
- Weight research
Points in its favour in the literature:
- Complementary mechanism to GLP-1 agonists
- Human trial data emerging
Caveats and unknowns:
- Investigational, not approved
- Limited standalone human data
- Safety profile still being defined
Handling & reference data
Route in published researchSubcutaneous injection is the route most commonly described in the research literature. Once-weekly in the trials.
Reported half-lifelong-acting, weekly
Published clinical / research context (not instructions)Trials escalated toward ~2.4 mg once weekly (investigational).
Storage (lyophilised)Lyophilised (freeze-dried) powder: refrigerate at 2–8 °C short-term, or freeze at −20 °C or below for long-term storage. Keep sealed and out of light.
Reconstituted solutionOnce reconstituted: keep refrigerated (2–8 °C), protect from light, do not freeze. With bacteriostatic water, commonly used within ~4 weeks; with plain sterile water, within ~24–48 h.
Worked reconstitution example (arithmetic only)e.g. 5 mg vial + 2 mL → 2.5 mg/mL.
Available research formats
| Strength | SKU |
|---|---|
| 5mg | CGL5 |
| 10mg | CGL10 |
Current pricing (THB with USD/GBP conversion) is shown live in the catalogue, which also has a transparent U-100 reconstitution calculator.